mobocertinib + rifampin

Mobocertinib + rifampin is a combination of two drugs: **mobocertinib**, an oral, irreversible tyrosine kinase inhibitor targeting epidermal growth factor receptor (EGFR) exon 20 insertion mutations, and **rifampin**, an oral antibiotic and strong inducer of cytochrome P450 3A (CYP3A). Mobocertinib is approved for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy[1][3][4]. Rifampin is primarily used to treat tuberculosis and other bacterial infections, but in this combination, its presence is notable because strong CYP3A inducers like rifampin greatly reduce mobocertinib blood levels, and co-administration is strongly contraindicated[2][5].

Brand names

Exkivity

Other names

mobocertinib + rifampin